posit updat highlight resili despit impress financi
result includ non-gaap ep beat consensu
revenu outpac consensu non-gaap oper margin
remain unsurpass sinc dynam includ delay
recent initi clinic trial
reduct offic visit caus fewer new patient start reduc office-
base administr leverag strength virtual medicin
biosimilar broad portfolio eventu transit
commerci payor govern optimist ahead key clinic
trial readout updat model reflect actual guidanc detail insid
revenu exceed our/consensu estim sg expens
consensu estimate ask sustain non-
oper margin understand certain expens may
defer thu impact futur quarter long-term revenu outlook around
consensu estimate increas updat sale
estim includ aimovig repatha prolia exhibit
clinic trial readout time remain track despit impact
recent initi studi believ major focu nsclc
monotherapi sotorasib expect read base
enrol complet registr import month dor
orr view bar monotherapi approv nsclc
base docetaxel
virtual featur addit sotorasib monotherapi data
tumor pancreat appendic endometri expect
data elucid path forward variou tumor type beyond nsclc
could determin feasibl pursu monotherapi approach vs go
straight combin encourag progress hle bite platform
data expect throughout
biosimilar revenu beat consensu suggest
inflect counter-cycl growth driver view partial hedg
eros biolog growth factor suspect
pandem result pressur healthcar econom could acceler uptak
biosimilar profit busi unit base
manufactur scale accord
bd capit alloc remain top prioriti accord
manag oncolog immunolog remain therapeut area focu
continu dividend share repurchas updat model
actual adjust support vs prior exhibit
biotechnolog
discov
develop manufactur market
cancer autoimmun
diseas specialti market
year price histori
analyst certif import disclosur see disclosur
estim amgen top line remain rel stabl
margin improv sg decreas
percentag sale expect volum increas growth
product continu increas market penetr pipelin
estim revenu remain rel stabl
next ten year margin expand manag
track record financi disciplin top line believ
posit maintain long-term revenu stabil
matur product declin new product continu grow
pipelin deliv steadi flow new product
offer dividend yield believ provid valuat
updat data kra inhibitor
estim sell price two experiment product
low price increas exist product would
meaning upsid earn estim
experiment compound launch sooner
estim would result addit upsid estim
repatha growth slow pipelin asset fail launch
estim gradual declin revenu ep scenario
estim stock could valu rang
next month
price target base dcf valuat assum wacc residu growth rate
due declin in-lin product off-set new product pipelin long term see top-lin essenti stabl
forecast peak sale tezepelumab base probabl success base probabl
success omecamtiv base probabl success
believ greatest risk stock next five year disrupt continu success repatha fda
approv experiment therapi romosozumab continu success launch aimovig migrain biosimilar abp abp
abp key risk project would occur repatha growth slow experiment therapi biosimilar fail
launch
exhibit actual vs oppenheim consensu estim
exhibit revenu forecast increas steadili
incom growth oppenheimerest vs oppenheim consensu estimate actual vs consensu oppenheim estimate consensu updat midpoint total non-gaap cog margin rate incom ep growth oppenheimerest vs oppenheim consensu estimate actual vs consensu oppenheim estimate consensu revenu estim pipelinehpt secondari ckdprimari caredenosumaboncologyauto-immunegrowth factorsoth inc
exhibit long-term revenu forecast around consensu
exhibit result reflect strong resili despit disrupt relat sale
estim base potenti impact specif product segment
exhibit bd capit alloc remain top prioriti oncolog immunolog
remain therapeut area focu continu dividend share repurchas
exhibit dcf valuat support pt
amgndiscount analysi except per-shar data revenu incom bgne chang work work capit valu growth valu oppenheim estim compani reportsequ valu per sharetermin valu growth rate inc
net incom equiti invest bgne
